Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Targeting the GM-CSF receptor for the treatment of CNS autoimmunity.

Ifergan I, Davidson TS, Kebir H, Xu D, Palacios-Macapagal D, Cann J, Rodgers JM, Hunter ZN, Pittet CL, Beddow S, Jones CA, Prat A, Sleeman MA, Miller SD.

J Autoimmun. 2017 Nov;84:1-11. doi: 10.1016/j.jaut.2017.06.005. Epub 2017 Jun 20.

2.

Biodegradable antigen-associated PLG nanoparticles tolerize Th2-mediated allergic airway inflammation pre- and postsensitization.

Smarr CB, Yap WT, Neef TP, Pearson RM, Hunter ZN, Ifergan I, Getts DR, Bryce PJ, Shea LD, Miller SD.

Proc Natl Acad Sci U S A. 2016 May 3;113(18):5059-64. doi: 10.1073/pnas.1505782113. Epub 2016 Apr 18.

3.

Targeted immunomodulation using antigen-conjugated nanoparticles.

McCarthy DP, Hunter ZN, Chackerian B, Shea LD, Miller SD.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014 May-Jun;6(3):298-315. doi: 10.1002/wnan.1263. Epub 2014 Mar 10. Review.

4.

Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo.

Eaton VL, Vasquez KO, Goings GE, Hunter ZN, Peterson JD, Miller SD.

J Neuroinflammation. 2013 Nov 15;10:138. doi: 10.1186/1742-2094-10-138.

5.

Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis.

Getts DR, Martin AJ, McCarthy DP, Terry RL, Hunter ZN, Yap WT, Getts MT, Pleiss M, Luo X, King NJ, Shea LD, Miller SD.

Nat Biotechnol. 2012 Dec;30(12):1217-24. doi: 10.1038/nbt.2434. Epub 2012 Nov 18.

Supplemental Content

Loading ...
Support Center